Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live

Cantor Fitzgerald & Paragon Therapeutics

2 shared events · Importance 3 · Last updated Sep 09, 2026

Importance
3
Shared Events
2
Actions
1
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
55
Regulatory
Cantor Fitzgerald: Analyst firm that published a negative note on the FDA briefing documents.
Paragon Therapeutics: Central company facing regulatory rejection and multiple securities fraud lawsuits; stock collapsed over 78%.
Jul 27, 2026 · 305 articles
45
Regulatory
Cantor Fitzgerald: Cantor Fitzgerald analyst Kristen Kluska published an investor note stating the FDA briefing documents paint an ugly picture and raise concerns about the integrity of data collection, a view cited in the complaint.
Paragon Therapeutics: Capricor is the central defendant in the securities fraud class action and the issuer whose Deramiocel BLA and statistical analysis plan changes are at the heart of the dispute. The litigation, the 64% stock drop, and the extended PDUFA date to November 22, 2026 leave its equity under heavy pressure and its regulatory path uncertain.
Aug 10, 2026 · 267 articles
ERGEN INTELLIGENCE
Explore this relationship live

Track how Cantor Fitzgerald and Paragon Therapeutics interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.